AbbVie Inc.

ABBV

US00287Y1091

AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).

Sector

Pharmaceuticals

Calendar

26/07/2024 - Q2 2024 Earnings Release (Projected)

Related indices

S&P 500

More about the company

Income Statement Evolution

More financial data

Ratings for AbbVie Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

170.8 USD

Average target price

183.2 USD

Spread / Average Target

+7.31%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
ABBVIE INC.	+10.18%	302B
ELI LILLY AND COMPANY	+55.19%	815B
NOVO NORDISK A/S	+47.26%	654B
JOHNSON & JOHNSON	-6.09%	354B
MERCK & CO., INC.	+21.92%	337B
ASTRAZENECA PLC	+18.40%	247B
ROCHE HOLDING AG	+3.64%	229B
NOVARTIS AG	+12.98%	219B
AMGEN INC.	+10.86%	171B
PFIZER, INC.	-2.78%	159B

Other Pharmaceuticals

Market Closed - Nyse Other stock markets 01:31:40 26/06/2024 am IST			5-day change	1st Jan Change
170.8 ^USD	-1.15%		-0.36%	+10.18%

25/06	FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update	DJ
25/06	AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	MT

FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo -- Update	25/06	DJ
AbbVie Issues Regulatory Update on New Drug Application for ABBV-951 to Treat Parkinson's Disease	25/06	MT
FDA Again Rejects AbbVie Parkinson's Drug/Pump Combo	25/06	DJ
US FDA declines to approve AbbVie's Parkinson's disease therapy	25/06	RE
AbbVie Provides U.S. Regulatory Update on ABBV-951 (Foscarbidopa/Foslevodopa)	25/06	CI
AbbVie Keeps Quarterly Dividend at $1.55 per Share, Payable Aug. 15 to Shareholders of Record July 15	21/06	MT
AbbVie Inc. Declares Quarterly Cash Dividend, Payable on August 15, 2024	21/06	CI
AbbVie Says Skyrizi Gets FDA Approval For Ulcerative Colitis	20/06	MT
US FDA proposes to remove switching study requirement for biosimilars	20/06	RE
AbbVie Inc. Announces Board of Directors Changes	20/06	CI
AbbVie: FDA approval in ulcerative colitis	19/06	CF
U.S. FDA Approves Skyrizi® (Risankizumab-Rzaa) for Ulcerative Colitis, Expanding Abbvie's Portfolio Across Inflammatory Bowel Disease	19/06	CI
AbbVie's Skyrizi Gets FDA Approval to Treat Certain Instances of Ulcerative Colitis	19/06	DJ
Piper Sandler Adjusts Price Target on AbbVie to $190 From $185	18/06	MT
Future prospects for AI	18/06
AbbVie Says Investors Should Sit Out Tutanota Mini-Tender Offer	15/06	MT
AbbVie inks immune disorder drug licensing deal with China's FutureGen	13/06	RE
AbbVie, FutureGen in License Pact for Inflammatory Bowel Disease Drug	13/06	DJ
AbbVie, FutureGen to Develop Potential Inflammatory Bowel Disease Treatment	13/06	MT
Transcript : AbbVie Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-12-2024 10:00 AM	12/06
Alvotech Expands Alliance with STADA to Include Denosumab Biosimilar	11/06	MT
Three companies to bet on medical AI	10/06
Global markets live: ABB, Roche, Microsoft, Apple, Tesla...	10/06
AbbVie's Blood Cancer Treatment Receives Scottish Approval	10/06	MT
Top law firms in US opioid lawsuits to get hundreds of millions in fees	08/06	RE